2025
Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients
Chen J, Levy A, Tian A, Huang X, Cai G, Fidelle M, Rauber C, Ly P, Pizzato E, Sitterle L, Piccinno G, Liu P, Durand S, Mao M, Zhao L, Iebba V, Felchle H, Mallard de La Varende A, Fischer J, Thomas S, Greten T, Jones J, Monge C, Demaria S, Formenti S, Belluomini L, Dionisi V, Massard C, Blanchard P, Robert C, Quevrin C, Lopes E, Clémenson C, Mondini M, Meziani L, Zhan Y, Zeng C, Cai Q, Morel D, Sun R, Laurent P, Mangoni M, Di Cataldo V, Arilli C, Trommer M, Wegen S, Neppl S, Riechelmann R, Camandaroba M, Neto E, Fournier P, Segata N, Holicek P, Galluzzi L, Buqué A, Alves Costa Silva C, Derosa L, Kroemer G, Chen C, Zitvogel L, Deutsch E. Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients. Cancer Cell 2025, 43: 361-379.e10. PMID: 40068595, PMCID: PMC11907695, DOI: 10.1016/j.ccell.2025.02.010.Peer-Reviewed Original ResearchConceptsPD-L1 blockadeLow-dose irradiationCancer patientsAbscopal effectEfficacy of PD-L1 blockadeCD8<sup>+</sup> T cell activationBenefit of immune checkpoint inhibitorsClinical benefit of immune checkpoint inhibitorsTumor-draining lymph nodesSecond-line immunotherapyImmune checkpoint inhibitorsPhase 2 studyProspective clinical trialTumor-bearing miceCohort of cancer patientsT cell activationMetastatic cancer patientsAnti-cancer efficacyCheckpoint inhibitorsLocal radiotherapyPD-L1Clinical benefitLymph nodesOptimal dosimetryRetrospective cohort
2024
Programmable Bacteria‐Based Biohybrids as Living Biotherapeutics for Enhanced Cancer Sonodynamic‐Immunotherapy
Wang C, Chen L, Zhu J, Wang C, Li M, Miao Y, Liu N, Ji Z, Pan F, Liu Y, Zhu J, Yang Y, Chen Q. Programmable Bacteria‐Based Biohybrids as Living Biotherapeutics for Enhanced Cancer Sonodynamic‐Immunotherapy. Advanced Functional Materials 2024, 34 DOI: 10.1002/adfm.202316092.Peer-Reviewed Original ResearchSonodynamic therapyAntitumor immune responseTumor-associated antigensImmune memory responsePrevent tumor recurrenceInhibit tumor metastasisOrthotopic colorectal tumorsAbscopal effectTumor recurrenceEffective sonodynamic therapyTumor siteNano-sonosensitizersTumor hypoxiaPathogen-associated molecular patternsColorectal tumorsMemory responsesTherapeutic delivery systemsTumor metastasisImmune responseTumorLive biotherapeuticsMetastasisBacterial pathogen-associated molecular patternsMolecular patternsOverexpressing catalase
2023
Integrating [18F]-Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography with Radiation Therapy and Immunomodulation in Precision Therapy for Solid Tumors
Prendergast C, Lopci E, Seban R, De Jong D, Ammari S, Aneja S, Lévy A, Sajan A, Salvatore M, Cappacione K, Schwartz L, Deutsch E, Dercle L. Integrating [18F]-Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography with Radiation Therapy and Immunomodulation in Precision Therapy for Solid Tumors. Cancers 2023, 15: 5179. PMID: 37958353, PMCID: PMC10648321, DOI: 10.3390/cancers15215179.Peer-Reviewed Original ResearchPET/CTRadiation therapyPositron emission tomographySolid tumorsEmission tomographyPrecision therapyCombination of RTFDG positron emission tomographyFluorodeoxyglucose positron emission tomographyDistant tumor sitesQuality of careComputed tomography (CT) imagingAdverse eventsAbscopal effectJoint guidelinesTreatment responseComputed tomographyIO administrationTumor siteTherapyTomography imagingIncremental valueTomographyTumorsCTCancer immunotherapy with enveloped self-amplifying mRNA CARG-2020 that modulates IL-12, IL-17 and PD-L1 pathways to prevent tumor recurrence
Chen J, Madina B, Ahmadi E, Yarovinsky T, Krady M, Meehan E, Wang I, Ye X, Pitmon E, Ma X, Almassian B, Nakaar V, Wang K. Cancer immunotherapy with enveloped self-amplifying mRNA CARG-2020 that modulates IL-12, IL-17 and PD-L1 pathways to prevent tumor recurrence. Acta Pharmaceutica Sinica B 2023, 14: 335-349. PMID: 38261838, PMCID: PMC10792965, DOI: 10.1016/j.apsb.2023.08.034.Peer-Reviewed Original ResearchCancer immunotherapyTumor recurrenceShort hairpin RNASurvival benefitIL-12Immune mechanismsLong-term survival benefitIL-17 receptor ACancer-promoting inflammationLarge established tumorsMultiple immune mechanismsPD-L1 pathwayT cell exhaustionDeath ligand 1Human cancer immunotherapySelf-amplifying mRNATumor-bearing miceVirus-like vesiclesMechanism of protectionCombined immunomodulationContralateral tumorsIL-17Established tumorsAbscopal effectImmunological memory
2021
HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy
Arora S, Catania R, Borhani A, Horvat N, Fowler K, Harmath C. HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy. Abdominal Radiology 2021, 46: 3686-3697. PMID: 34195886, DOI: 10.1007/s00261-021-03192-8.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaTumor biologyHCC tumor biologyRare responsesTreatment hepatocellular carcinomaPost-treatment responsePrognostic featuresAbscopal effectAdverse outcomesCancer deathIdeal therapyEffective therapyImaging featuresDisease evolveIndividual patientsLiver cancerMore therapiesTumor behaviorTreatment planParticular tumorTherapyClinical useTreatment planningPatientsTumors
2020
Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non–small-cell lung carcinoma
Boulle G, Velut Y, Mansuet-Lupo A, Gibault L, Blons H, Fournel L, Boni A, Cremer I, Wislez M, Duchatelle V, Trédaniel J, Hammond S, Herbst R, Alifano M, Giraud P, Damotte D. Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non–small-cell lung carcinoma. European Journal Of Cancer 2020, 135: 221-229. PMID: 32610210, DOI: 10.1016/j.ejca.2020.04.040.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overB7-H1 AntigenCarcinoma, Non-Small-Cell LungCD8-Positive T-LymphocytesChemoradiotherapyChemoradiotherapy, AdjuvantFemaleForkhead Transcription FactorsHumansLung NeoplasmsLymphocytes, Tumor-InfiltratingMaleMiddle AgedNeoplasm StagingRetrospective StudiesTime FactorsTreatment OutcomeTumor MicroenvironmentConceptsT-cell densityCell lung carcinomaN2 NSCLCPatient survivalLung carcinomaClinical dataT cellsRadiotherapy efficacyIII-N2 NSCLCSurgery/chemotherapyPD-L1 expressionStandard of careImmunogenic cell deathDouble-positive cellsAction of radiotherapyIII-N2Immune environmentAbscopal effectChemoradiotherapy efficacyImmune infiltrationImmune cellsPositive cellsMultivariate analysisRadiotherapyTumor samples
2018
A phase I/II multi-center study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) for patients with locally advanced esophageal squamous cell carcinoma (ESCC).
Giuroiu I, Ku G, Leichman L, Du K, Oh P, Levinson B, Iqbal S, Thomas C, Wu J. A phase I/II multi-center study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) for patients with locally advanced esophageal squamous cell carcinoma (ESCC). Journal Of Clinical Oncology 2018, 36: tps199-tps199. DOI: 10.1200/jco.2018.36.4_suppl.tps199.Peer-Reviewed Original ResearchEsophageal squamous cell carcinomaAdvanced esophageal squamous cell carcinomaPathologic complete responseOverall survivalClinical CRRadiation therapyMedian progression-free survivalPhase IEfficacy of nivolumabCarboplatin/paclitaxelOverall survival benefitProgression-free survivalKaplan-Meier curvesSquamous cell carcinomaMulti-center studyLast dosePrimary endpointUnacceptable toxicitySurvival benefitComplete responseMeier curvesAbscopal effectCell carcinomaExtensive tumorsEsophageal cancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply